381 related articles for article (PubMed ID: 28299663)
1. RUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML.
Hyde RK; Liu P; Friedman AD
Adv Exp Med Biol; 2017; 962():265-282. PubMed ID: 28299663
[TBL] [Abstract][Full Text] [Related]
2. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
Metzeler KH; Bloomfield CD
Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
[TBL] [Abstract][Full Text] [Related]
3. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
4. Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.
Castilla LH; Bushweller JH
Adv Exp Med Biol; 2017; 962():229-244. PubMed ID: 28299661
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.
Zhao X; Chen A; Yan X; Zhang Y; He F; Hayashi Y; Dong Y; Rao Y; Li B; Conway RM; Maiques-Diaz A; Elf SE; Huang N; Zuber J; Xiao Z; Tse W; Tenen DG; Wang Q; Chen W; Mulloy JC; Nimer SD; Huang G
Blood; 2014 Mar; 123(11):1729-38. PubMed ID: 24449215
[TBL] [Abstract][Full Text] [Related]
6. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
Engel ME; Hiebert SW
Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
Harada Y; Harada H
J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
[TBL] [Abstract][Full Text] [Related]
8. Autonomous feedback loop of RUNX1-p53-CBFB in acute myeloid leukemia cells.
Morita K; Noura M; Tokushige C; Maeda S; Kiyose H; Kashiwazaki G; Taniguchi J; Bando T; Yoshida K; Ozaki T; Matsuo H; Ogawa S; Liu PP; Nakahata T; Sugiyama H; Adachi S; Kamikubo Y
Sci Rep; 2017 Nov; 7(1):16604. PubMed ID: 29192243
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y; Kawashima N; Atsuta Y; Sugiura I; Sawa M; Dobashi N; Yokoyama H; Doki N; Tomita A; Kiguchi T; Koh S; Kanamori H; Iriyama N; Kohno A; Moriuchi Y; Asada N; Hirano D; Togitani K; Sakura T; Hagihara M; Tomikawa T; Yokoyama Y; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H
Blood Adv; 2020 Jan; 4(1):66-75. PubMed ID: 31899799
[TBL] [Abstract][Full Text] [Related]
10. Integrative analysis of RUNX1 downstream pathways and target genes.
Michaud J; Simpson KM; Escher R; Buchet-Poyau K; Beissbarth T; Carmichael C; Ritchie ME; Schütz F; Cannon P; Liu M; Shen X; Ito Y; Raskind WH; Horwitz MS; Osato M; Turner DR; Speed TP; Kavallaris M; Smyth GK; Scott HS
BMC Genomics; 2008 Jul; 9():363. PubMed ID: 18671852
[TBL] [Abstract][Full Text] [Related]
11. Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma.
Kundu M; Compton S; Garrett-Beal L; Stacy T; Starost MF; Eckhaus M; Speck NA; Liu PP
Blood; 2005 Nov; 106(10):3621-4. PubMed ID: 16051740
[TBL] [Abstract][Full Text] [Related]
12. RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM).
Schlegelberger B; Heller PG
Semin Hematol; 2017 Apr; 54(2):75-80. PubMed ID: 28637620
[TBL] [Abstract][Full Text] [Related]
13. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
14. Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia.
Ganly P; Walker LC; Morris CM
Leuk Lymphoma; 2004 Jan; 45(1):1-10. PubMed ID: 15061191
[TBL] [Abstract][Full Text] [Related]
15. Core binding factor genes and human leukemia.
Hart SM; Foroni L
Haematologica; 2002 Dec; 87(12):1307-23. PubMed ID: 12495904
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with
Qin W; Chen X; Shen HJ; Wang Z; Cai X; Jiang N; Hua H
Turk J Haematol; 2022 Jun; 39(2):84-93. PubMed ID: 35445594
[TBL] [Abstract][Full Text] [Related]
17. The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies.
Yokota A; Huo L; Lan F; Wu J; Huang G
Mol Cells; 2020 Feb; 43(2):145-152. PubMed ID: 31964134
[TBL] [Abstract][Full Text] [Related]
18. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
19. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
Migas A; Savva N; Mishkova O; Aleinikova OV
Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
[TBL] [Abstract][Full Text] [Related]
20. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction.
Cunningham L; Finckbeiner S; Hyde RK; Southall N; Marugan J; Yedavalli VR; Dehdashti SJ; Reinhold WC; Alemu L; Zhao L; Yeh JR; Sood R; Pommier Y; Austin CP; Jeang KT; Zheng W; Liu P
Proc Natl Acad Sci U S A; 2012 Sep; 109(36):14592-7. PubMed ID: 22912405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
